支气管动脉灌注化疗加免疫治疗肺癌伴恶性胸水的临床研究  

The efficacy of bronchial artery infusion chemotherapy combined with immunotherapy for lung cancer with malignant hydrothorax

作　　者：偰利宇[1] 杨珏[2] 赵卫[1] 庞瑞麟[1] 向述天[1] 董学先[2] 胡继红[1] 李红芬[1] 段理[1] 

机构地区：[1]昆明医学院第一附属医院医学影像中心,650032 [2]云南省第一人民医院介入放射科

出　　处：《中国肺癌杂志》2002年第5期360-362,共3页Chinese Journal of Lung Cancer

摘　　要：目的　探讨支气管动脉灌注化疗加免疫治疗肺癌伴恶性胸水的价值。方法　将 75例肺癌伴恶性胸水患者随机分为两组 :试验组 38例 ,胸穿抽净胸水后向胸腔内注入化疗药物 (胸腔内化疗 ) ,再行支气管动脉灌注化疗加免疫治疗 ;对照组 37例 ,仅行胸腔内化疗。比较两组病例第 1疗程的疗效 (治疗肺癌疗效和控制胸水效果 )及 1、2年生存率。结果　第 1疗程治疗后 ,试验组治疗肺癌的总有效率为 31.5 8% ( 12 /38) ,对照组为 5 .41% ( 2 /37) ,两组间比较差异非常显著 ( χ2 =8.46 ,P <0 .0 1) ;试验组控制胸水的有效率为86 .84% ( 33/38) ,对照组为 6 4.86 % ( 2 4/37) ,两组间比较有显著性差异 ( χ2 =4.96 ,P <0 .0 5 )。试验组患者1、2年生存率分别为 6 5 .79% ( 2 5 /38)和 2 6 .32 % ( 10 /38) ,对照组为 40 .5 4% ( 15 /37)和 5 .41% ( 2 /37) ,前者明显高于后者 ( χ2 =4.80 ,P <0 .0 5 ;χ2 =6 .10 ,P <0 .0 5 )。结论　胸腔内化疗联合支气管动脉灌注化疗加免疫治疗肺癌伴恶性胸水 。Objective To explore the therapeutic effect of bronchial artery infusion chemotherapy combined with immunotherapy for lung cancer with malignant hydrothorax. Methods Seventy-five lung cancer patients with malignant hydrothorax were randomly divided into the two groups: 38 patients were given intrathoracic chemotherapy and bronchial artery infusion chemotherapy combined with immunotherapy as observing group; 37cases only received intrathoracic chemotherapy as control group. χ 2 assay was performed to analyze the efficacy (responses for lung cancer and hydrothorax control) after the first course of treatment and the 1-, 2-year survival rates in the two groups. Results After the first course of treatment, the total responses for lung cancer were 31.58% (12/38) and 5.41% (2/37) in the observing group and control group (χ 2=8.46, P<0.01) respectively ; and responses for hydrothorax control were 86.84% and 64.86% respectively (χ 2= 4.96, P<0.05). The 1- and 2-year survival rates in the observing group were 65.79% (25/38) and 26.32% (10/38) respectively, which were significantly higher than those of the control group (40.54% and 5.41%) respectively (χ 2=4.80, P<0.05; χ 2=6.10, P<0.05). Conclusion The intrathoracic chemotherapy combined with bronchial artery infusion chemotherapy and immunotherapy is quite effective in the treatment of lung cancer with malignant hydrothorax.

关 键 词：支气管动脉灌注化疗 免疫治疗 肺癌 恶性胸水 

分 类 号：R734.2[医药卫生—肿瘤]